ECB-ART-51938
J Otolaryngol Head Neck Surg
2023 Apr 24;521:30. doi: 10.1186/s40463-023-00626-9.
Show Gene links
Show Anatomy links
Canadian multidisciplinary expert consensus on the use of biologics in upper airways: a Delphi study.
Thamboo AV
,
Lee M
,
Bhutani M
,
Chan C
,
Chan Y
,
Chapman KR
,
Chin CJ
,
Connors L
,
Dorscheid D
,
Ellis AK
,
Gall RM
,
Godbout K
,
Janjua A
,
Javer A
,
Kilty S
,
Kim H
,
Kirkpatrick G
,
Lee JM
,
Leigh R
,
Lemiere C
,
Monteiro E
,
Neighbour H
,
Keith PK
,
Philteos G
,
Quirt J
,
Rotenberg B
,
Ruiz JC
,
Scott JR
,
Sommer DD
,
Sowerby L
,
Tewfik M
,
Waserman S
,
Witterick I
,
Wright ED
,
Yamashita C
,
Desrosiers M
.
???displayArticle.abstract???
BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) often coexists with lower airway disease. With the overlap between upper and lower airway disease, optimal management of the upper airways is undertaken in conjunction with that of the lower airways. Biologic therapy with targeted activity within the Type 2 inflammatory pathway can improve the clinical signs and symptoms of both upper and lower airway diseases. Knowledge gaps nevertheless exist in how best to approach patient care as a whole. There have been sixteen randomized, double-blind, placebo-controlled trails performed for CRSwNP targeted components of the Type 2 inflammatory pathway, notably interleukin (IL)-4, IL-5 and IL-13, IL- 5R, IL-33, and immunoglobulin (Ig)E. This white paper considers the perspectives of experts in various disciplines such as rhinology, allergy, and respirology across Canada, all of whom have unique and valuable insights to contribute on how to best approach patients with upper airway disease from a multidisciplinary perspective. METHODS: A Delphi Method process was utilized involving three rounds of questionnaires in which the first two were completed individually online and the third was discussed on a virtual platform with all the panelists. A national multidisciplinary expert panel of 34 certified specialists was created, composed of 16 rhinologists, 7 allergists, and 11 respirologists who evaluated the 20 original statements on a scale of 1-9 and provided comments. All ratings were quantitively reviewed by mean, median, mode, range, standard deviation and inter-rater reliability. Consensus was defined by relative interrater reliability measures-kappa coefficient ([Formula: see text]) value > 0.61. RESULTS: After three rounds, a total of 22 statements achieved consensus. This white paper only contains the final agreed upon statements and clear rationale and support for the statements regarding the use of biologics in patients with upper airway disease. CONCLUSION: This white paper provides guidance to Canadian physicians on the use of biologic therapy for the management of upper airway disease from a multidisciplinary perspective, but the medical and surgical regimen should ultimately be individualized to the patient. As more biologics become available and additional trials are published we will provide updated versions of this white paper every few years.
???displayArticle.pubmedLink??? 37095527
???displayArticle.link??? J Otolaryngol Head Neck Surg
References [+] :
Adappa,
Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease.
2018, Pubmed
Adappa, Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease. 2018, Pubmed
Akarcay, Do comorbidities influence objective and subjective recovery rates of nasal polyposis? 2010, Pubmed
Amine, Outcomes of endoscopy and computed tomography in patients with chronic rhinosinusitis. 2013, Pubmed
Bachert, Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial. 2016, Pubmed
Bachert, Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. 2019, Pubmed
Bachert, Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. 2020, Pubmed
Bachert, Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. 2017, Pubmed
Bachert, Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. 2022, Pubmed
Bachert, Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. 2010, Pubmed
Bachert, Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. 2001, Pubmed
Bachert, IL-5 synthesis is upregulated in human nasal polyp tissue. 1997, Pubmed
Bachert, EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. 2021, Pubmed
Bagnasco, Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. 2019, Pubmed
Bassiouni, Role of frontal sinus surgery in nasal polyp recurrence. 2013, Pubmed
Bateman, Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. 2015, Pubmed
Batra, Analysis of comorbidities and objective parameters in refractory chronic rhinosinusitis. 2013, Pubmed
Benninger, Early versus delayed endoscopic sinus surgery in patients with chronic rhinosinusitis: impact on health care utilization. 2015, Pubmed
Benninger, The development of the Rhinosinusitis Disability Index. 1997, Pubmed
Bosma, Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series. 2021, Pubmed
Bousquet, Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). 2008, Pubmed
Brescia, Nasal polyposis pathophysiology: Endotype and phenotype open issues. 2018, Pubmed
Burke, A multidisciplinary team case management approach reduces the burden of frequent asthma admissions. 2016, Pubmed
Cho, Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. 2014, Pubmed
Chu, Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis. 2019, Pubmed
DeConde, Response shift in quality of life after endoscopic sinus surgery for chronic rhinosinusitis. 2014, Pubmed
DeConde, Outcomes of complete vs targeted approaches to endoscopic sinus surgery. 2015, Pubmed
Deleuran, Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. 2020, Pubmed
Desrosiers, Canadian clinical practice guidelines for acute and chronic rhinosinusitis. 2011, Pubmed
Di Bona, Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study. 2017, Pubmed
Fan, Aspirin-exacerbated respiratory disease in China: a cohort investigation and literature review. 2012, Pubmed
Flinn, A prospective analysis of incidental paranasal sinus abnormalities on CT head scans. 1994, Pubmed
Fokkens, EUFOREA consensus on biologics for CRSwNP with or without asthma. 2019, Pubmed
Fokkens, EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. 2012, Pubmed
Fokkens, Executive summary of EPOS 2020 including integrated care pathways. 2020, Pubmed
Fong, Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes. 2021, Pubmed
Frohlich, Eosinophilic pulmonary complications of dupilumab in 2 patients with asthma and chronic rhinosinusitis with nasal polyps. 2022, Pubmed
Gaga, Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. 2000, Pubmed
Gevaert, Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. 2013, Pubmed
Gevaert, Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. 2020, Pubmed
Gevaert, Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. 2011, Pubmed
Gevaert, Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. 2006, Pubmed
Gliklich, Techniques for outcomes research in chronic sinusitis. 1995, Pubmed
Grose, Surgical outcomes in aspirin-exacerbated respiratory disease without aspirin desensitization. 2020, Pubmed
Guyatt, Measuring change over time: assessing the usefulness of evaluative instruments. 1987, Pubmed
Hamada, Impact of sinus surgery on type 2 airway and systemic inflammation in asthma. 2021, Pubmed
Han, Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. 2021, Pubmed
Hopkins, Does time to endoscopic sinus surgery impact outcomes in chronic rhinosinusitis? Retrospective analysis using the UK clinical practice research data. 2015, Pubmed
Hopkins, Psychometric validity of the 22-item Sinonasal Outcome Test. 2009, Pubmed
Iqbal, The role of biologics in chronic rhinosinusitis: a systematic review. 2020, Pubmed
Ivanova, Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. 2012, Pubmed
Jang, Aspirin sensitivity does not compromise quality-of-life outcomes in patients with Samter's triad. 2014, Pubmed
Jia, The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis. 2013, Pubmed
John Staniorski, Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population. 2018, Pubmed
Juniper, Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. 2005, Pubmed
Kamrava, University of pennsylvania smell identification on Iranian population. 2014, Pubmed
Kavanagh, Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma. 2021, Pubmed
Khan, The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. 2019, Pubmed
Kim, Usefulness of Nasal Endoscopy for Diagnosing Patients With Chronic Rhinosinusitis: A Meta-Analysis. 2020, Pubmed
Kohli, The prevalence of olfactory dysfunction in chronic rhinosinusitis. 2017, Pubmed
Laidlaw, Chronic Rhinosinusitis with Nasal Polyps and Asthma. 2021, Pubmed
Laidlaw, Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose. 2022, Pubmed
Landis, The measurement of observer agreement for categorical data. 1977, Pubmed
Landsberg, Systemic corticosteroids for allergic fungal rhinosinusitis and chronic rhinosinusitis with nasal polyposis: a comparative study. 2007, Pubmed
Lange, Comparison of different rating scales for the use in Delphi studies: different scales lead to different consensus and show different test-retest reliability. 2020, Pubmed
Leung, When do the risks of repeated courses of corticosteroids exceed the risks of surgery? 2014, Pubmed
Li, Role of p63/p73 in epithelial remodeling and their response to steroid treatment in nasal polyposis. 2011, Pubmed
Loftus, Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors. 2020, Pubmed
Lombardi, Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports. 2020, Pubmed
Mauer, Managing adult asthma: The 2019 GINA guidelines. 2020, Pubmed
McHugh, High tissue eosinophilia as a marker to predict recurrence for eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. 2018, Pubmed
Moore, Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. 2010, Pubmed
Muhonen, Appropriate extent of surgery for aspirin-exacerbated respiratory disease. 2020, Pubmed
Mukherjee, Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab. 2018, Pubmed
NULL, 2017, Pubmed
Orlandi, International consensus statement on allergy and rhinology: rhinosinusitis 2021. 2021, Pubmed
Orlandi, International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. 2016, Pubmed
Ortega, Combination biologic therapy for severe persistent asthma. 2019, Pubmed
Oykhman, Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. 2022, Pubmed
Parasher, Economic Evaluation of Dupilumab Versus Endoscopic Sinus Surgery for the Treatment of Chronic Rhinosinusitis With Nasal Polyps. 2022, Pubmed
Payne, Evidence for distinct histologic profile of nasal polyps with and without eosinophilia. 2011, Pubmed
Piccirillo, Psychometric and clinimetric validity of the 20-Item Sino-Nasal Outcome Test (SNOT-20). 2002, Pubmed
Pinto, A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. 2010, Pubmed
Quintanilla-Dieck, Comparison of disease-specific quality-of-life instruments in the assessment of chronic rhinosinusitis. 2012, Pubmed
Reddel, Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. 2022, Pubmed
Revicki, Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. 1998, Pubmed
Rosati, Relationships among allergic rhinitis, asthma, and chronic rhinosinusitis. 2016, Pubmed
Rosenfeld, Clinical practice guideline (update): adult sinusitis. 2015, Pubmed
Rotenberg, Postoperative care for Samter's triad patients undergoing endoscopic sinus surgery: a double-blinded, randomized controlled trial. 2011, Pubmed
Rudmik, Long-term utility outcomes in patients undergoing endoscopic sinus surgery. 2014, Pubmed
Rupani, Recent Insights into the Management of Inflammation in Asthma. 2021, Pubmed
Santanello, What are minimal important changes for asthma measures in a clinical trial? 1999, Pubmed
Scangas, Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps. 2021, Pubmed
Seccia, Management of Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Multidisciplinary Shared Approach. 2022, Pubmed
Seybt, The prevalence and effect of asthma on adults with chronic rhinosinusitis. 2007, Pubmed
Shen, Adverse events for biologics in patients with CRSwNP: A meta-analysis. 2022, Pubmed
Simpson, Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. 2020, Pubmed
Smith, Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions. 2018, Pubmed
Smith, Predictive factors and outcomes in endoscopic sinus surgery for chronic rhinosinusitis. 2005, Pubmed
Stevens, Associations Between Inflammatory Endotypes and Clinical Presentations in Chronic Rhinosinusitis. 2019, Pubmed
Szczeklik, Clinical features and diagnosis of aspirin induced asthma. 2000, Pubmed
Takabayashi, A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis. 2021, Pubmed
Tameez Ud Din, Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for? 2020, Pubmed
Tay, Comorbid "treatable traits" in difficult asthma: Current evidence and clinical evaluation. 2018, Pubmed
Thamboo, Canadian Rhinology Working Group consensus statement: biologic therapies for chronic rhinosinusitis. 2021, Pubmed , Echinobase
Toma, Stratification of SNOT-22 scores into mild, moderate or severe and relationship with other subjective instruments. 2016, Pubmed
Tversky, Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial. 2021, Pubmed
Vennera, Efficacy of omalizumab in the treatment of nasal polyps. 2011, Pubmed
Willsmore, Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series. 2019, Pubmed
Workman, Biologic therapies versus surgical management for aspirin-exacerbated respiratory disease: A review of preliminary data, efficacy, and cost. 2020, Pubmed
Yong, Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. 2021, Pubmed
Young, Long-term outcome analysis of endoscopic sinus surgery for chronic sinusitis. 2007, Pubmed
Yu, Down-regulation of EMP1 is associated with epithelial hyperplasia and metaplasia in nasal polyps. 2013, Pubmed